Celltrion is aggressively pursuing global clinical trials for a new antibody-drug conjugate (ADC) cancer treatment. Celltrion submitted an investigational new drug (IND) application to the U.S ...

The approval represents the seventh marketing authorisation of Celltrion in the country. Credit: © CELLTRION. The US Food and Drug Administration (FDA) has granted ...

Seoul, Jan 31 Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

(MENAFN- IANS) Seoul, Jan 31 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US ...

“Introducing both IV and SC formulations of AVTOZMA provides flexibility and a wider range of treatment options,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “This approval ...

Last summer, Celltrion revealed that its approved biosimilar to Humira had been added to the Costco Member Prescription Program—a drug discount card program that helps eligible Costco members ...

Celltrion Inc.’s biosimilar versions of Amgen Inc.’s blockbuster bone-strengthening drugs Prolia and Xgeva are blocked in the US until June 1 as part of a settlement agreement, according to a filing ...

Celltrion French Biosimilar Launch Celltrion has completed ... Eye on Pharma: aflibercept legal drama; PBM, Humira biosimilars; denosumab regulatory review. The Center for Biosimilars ®. October 15, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...